Niacin (vitamin B3)

Niacin (vitamin B3)

Best for

Raise cellular NAD+ levels

Large effect, needs confirmation · 1000–1500 mg/day for 4–48 weeks · 7 studies , n=184

46 papers · 4 claims · 94 outcomes scored · 4 positive

Outcomes

What niacin (vitamin b3) actually does, by outcome

Each row is one outcome with effect size, evidence base, the dose that worked in trials, and time to first effect. Magnitude tiers come from native-unit MCID where available, Cohen's d otherwise.

Outcome Effect Evidence Dose Weeks Rank
Raise cellular NAD+ levels Large effect, needs confirmation
large
7 RCTs n=184 1000–1500 mg 4–48 wk #2/2
Raise good cholesterol levels Likely benefit
moderate
17 meta-analyses n=199k Meta-analyzed 500–3000 mg 6–166 wk #2/71
Lower bad and total cholesterol Proven benefit
moderate
12 meta-analyses n=163k Meta-analyzed 500–3000 mg 8–166 wk #3/103
Lower triglycerides Likely modest benefit
small
11 meta-analyses n=158k Meta-analyzed 500–2000 mg 8–166 wk #2/89
Buy well

Recommended Niacin (vitamin B3) products

Real products that dose Niacin (vitamin B3) where the research does, in a clean formulation, from brands we've audited. We only list ones we'd stand behind.

Chosen for adequate Niacin (vitamin B3) dosing vs. the studied range, a clean formulation (grade A–C), and independent brand-quality audits. Not sponsored.

Risk profile

Adverse events and known drug interactions

Safety events

hepatitis / hepatic toxicity severe
Revascularization (CABG, PCI, carotid endarterectomy) severe
Stroke severe
vasovagal syncope severe
hepatic encephalopathy severe
severe coagulopathy severe
hemodynamic instability / hypotension severe
Flushing moderate

Drug interactions

Isoniazid major decreases concentration
Cisplatin major decreases effect
Oxaliplatin major decreases effect
Antineoplastic Agents major decreases effect
Warfarin major increases toxicity
Indomethacin moderate decreases effect
MK-0524 moderate decreases effect
Laropiprant (DP1 Antagonist) moderate decreases effect
other moderate decreases effect
Laropiprant (PGD2 Receptor Antagonist) moderate decreases effect

Co-studied with

Supplements that share evidence with niacin (vitamin b3)

  • Drug:Simvastatin 21 shared outcomes · d=0.47
  • Drug:Ezetimibe 3 shared outcomes · d=0.10

Sources

  1. 1. Measuring flushing symptoms with extended-release niacin using the flushing symptom questionnaire: results from a randomised placebo-controlled clinical trial. (2008)
  2. 2. Relationship between glycemic status and progression of carotid intima-media thickness during treatment with combined statin and extended-release niacin in ARBITER 2. (2007)
  3. 3. Short-term effects of extended-release niacin on endothelial function in HIV-infected patients on stable antiretroviral therapy. (2010)
  4. 4. Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial. (2011)
  5. 5. Effects of prescription niacin and omega-3 fatty acids on lipids and vascular function in metabolic syndrome: a randomized controlled trial. (2012)
  6. 6. MRI-measured regression of carotid atherosclerosis induced by statins with and without niacin in a randomised controlled trial: the NIA plaque study. (2013)
  7. 7. Effect of extended-release niacin on serum lipids and on endothelial function in adults with sickle cell anemia and low high-density lipoprotein cholesterol levels. (2013)
  8. 8. Pharmacological measures to increase HDL-C among high risk isolated low HDL cases: a randomized study amongst north Indians. (2013)
  9. 9. Effect of extended-release niacin on cardiovascular events and kidney function in chronic kidney disease: a post hoc analysis of the AIM-HIGH trial. (2015)
  10. 10. Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control. (2015)

Generated August 14, 2026

Want personalized recommendations?

Show me what works for me